Gemsol 40 mg/ml concentrato per soluzione per infusione

DRUG2 trials

Sponsors

AstraZeneca AB, Eir Biotherapies S.r.l.

Conditions

Advanced Hepatobiliary CancerDuctal adenocarcinoma of pancreasLocally advancednon-resectable pancreatic adenocarcinoma

Phase 1

RR001 in Combination with Chemotherapy for Patients with Locally Advanced Pancreatic Adenocarcinoma: Open-label, Non-randomized Dose Escalation Phase I/IIa Study

RecruitingCTIS2024-516019-26-00

Eir Biotherapies S.r.l.Ductal adenocarcinoma of pancreas, Locally advanced, non-resectable pancreatic adenocarcinoma

Start: 2025-06-25Target: 18Updated: 2025-12-09

Phase 2

A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)

RecruitingCTIS2022-502317-29-00

AstraZeneca ABAdvanced Hepatobiliary Cancer

Start: 2023-07-12Target: 60Updated: 2025-12-11